Clinical Trial Results:
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single
Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent
KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung
Cancer (NSCLC) (RAMP 202)
Summary
|
|
EudraCT number |
2020-004265-39 |
Trial protocol |
DE IT ES |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Nov 2024
|
First version publication date |
06 Nov 2024
|
Other versions |
|
Summary report(s) |
Synopsis_VS-6766-202 CSR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.